Stockscreener 앱 받기
4.95
2.37%
-0.12
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com Australia
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
(SGMT) On The My Stocks Page - Stock Traders Daily
Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha
Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com
How To Trade (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Sagimet Biosciences to Present at Piper Sandler Healthcare Conference | SGMT Stock News - StockTitan
Sagimet Biosciences participates ik,on No - TipRanks
Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDthe Liver Meeting 2024 - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com
Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - The Manila Times
Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire
Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com
Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com
Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World
Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks
Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sagimet's Denifanstat Earns FDA Breakthrough Status; Reports $170M Cash Position | SGMT Stock News - StockTitan
Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com
UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada
Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha
SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat
Sagimet Biosciences initiated with a Buy at UBS - TipRanks
Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St
Trend Tracker for (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News
2.88%
2.65%
자본화:
|
볼륨(24시간):